Sacituzumab tirumotecan
As of the edition of 20 October 2026, Sacituzumab tirumotecan is an antibody drug conjugate: in active development; acts on TACSTD2 and TOP1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Antibody drug conjugate
- Registered trials
- 106, 0 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 2 | 0 |
| Phase 1 | 2 | 0 | 2 | 0 |
| Phase 2 | 76 | 1 | 75 | 0 |
| Phase 3 | 26 | 0 | 26 | 0 |
| All trials | 106 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Klus Pharma | Lead sponsor of trials | 2020 to now |
| Sichuan Kelun-Biotech Biopharmaceutical | Lead sponsor of trials | 2022 to now |
| Merck & Co. | Lead sponsor of trials | 2023 to now |
| Convalife | Lead sponsor of trials | 2025 to now |
| Eddingpharm | Lead sponsor of trials | 2026 to now |